BAIYUNSHAN PH - Announcement of Resolutions of the Second Meeting of the 10th Board of Directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
BAIYUNSHAN PH - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
The Company does not make any statement and expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by the content.
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to publish the information published by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange (www.sse.com.cn)
The full Chinese text of the announcement of the resolution of the second meeting of the 10th Board of Directors of the Company is for reference only.
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
board of directors
Guangzhou, China, June 22, 2026
As of the date of this announcement, the company’s board of directors includes (i) executive directors Mr. Chen Jiehui, Mr. Yuan Cheng, Mr. Cheng Hongjin,
Mr. Tang Heping, Ms. Liu Ming and Mr. Liu Hong; (ii) Non-executive Director Mr. Huang Jiyuan; and (iii) Independent Non-executive Director Mr. Huang Longde, Ms. Sun Baoqing, Mr. Wu Xiangneng and Mr. Yang Yinbao.
Securities code: 600332 Securities abbreviation: Baiyunshan Announcement number: 2026-037
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the Second Meeting of the Tenth Board of Directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in this announcement, and that the contents of this announcement contain no false records, misleading statements or major omissions. bear legal responsibility for the authenticity, accuracy and completeness of the content.
The second session of the 10th Board of Directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. ("the Company", the "Company")
Notice of the meeting (the "Meeting") was sent by email on June 15, 2026, and the notice was issued on June 22, 2026.
The meeting will be held by communication voting. This meeting was chaired by Mr. Chen Jiehui, Chairman of the Company. The meeting shall
11 directors attended the meeting, and 11 directors actually attended the meeting. The convening and holding of the meeting complied with the "Company
Law and Articles of Association.
After deliberation and voting by the directors, the meeting reviewed and approved the following proposals:
- The Company’s 2026 “Improving Quality, Efficiency and Focusing on Returns” action plan (for details, please see the Company’s Daily
Announcement No. 2026-038 dated June 22, 2026)
Voting results: 11 votes in favor, 0 votes against, and 0 abstentions. This motion was approved.
- Regarding the formulation of the "Salary Guidelines for Directors and Senior Management of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd."
Proposal on "Remuneration Management Measures" (full text is available on the website of Shanghai Stock Exchange)
Voting results: 11 votes in favor, 0 votes against, and 0 abstentions. This motion was approved.
This proposal has been reviewed by the Nomination and Remuneration Committee of the 10th Board of Directors of the Company at the 1st meeting in 2026
Passed.
This proposal still needs to be submitted to the company's shareholders' meeting for review.
- Proposal on the 2026 remuneration of employee representative director Mr. Liu Hong
Mr. Liu Hong complies with the salary management regulations corresponding to his position in the company and will not receive any additional director's salary.
salary or allowance. Mr. Liu Hong is currently the director of the company’s scientific research project management department (doctoral (postdoctoral) workstation).
The total salary payable from the company in 2026 is expected to not exceed 887,000 yuan (tax included) (RMB,
The same below), including but not limited to the salary, benefits, etc. received from the company. The specific salary must be determined according to
Conduct assessment and adjustments in accordance with the company's salary management methods and related systems.
Voting results: 10 votes in favor, 0 votes against, and 0 abstentions. This motion was reviewed and approved.
Mr. Liu Hong, the representative director of the company, abstained from voting on the proposal.
This proposal has been reviewed by the Nomination and Remuneration Committee of the 10th Board of Directors of the Company at the 1st meeting in 2026
Passed.
This proposal still needs to be submitted to the company's shareholders' meeting for review.
- Regarding the formulation of the "Senior Managers of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. 2026"
Proposal on "Remuneration Plan" (full text is available on the website of Shanghai Stock Exchange)
This proposal has been reviewed by the Nomination and Remuneration Committee of the 10th Board of Directors of the Company at the 1st meeting in 2026
Passed.
Voting results: 11 votes in favor, 0 votes against, and 0 abstentions. This motion was approved.
- Proposal on terminating Guangyao Baiyunshan affordable rental housing and talent apartment construction project
On June 13, 2023, the second meeting of the company's ninth board of directors reviewed and approved the "About Guangyao Bai"
Yunshan Affordable Rental Housing and Talent Apartment Construction Project", allowing the company to use its own stock land
Construction of affordable rental housing and talent apartment project ("Project", "Project"), total project investment
The amount is 1,082.8603 million yuan, and the source of funds is self-raised funds and bank loans. For details, see
Company Announcement No. 2023-032, dated June 13, 2023.
Affected by major factors such as the changing real estate market environment and adjustments to Guangzhou’s affordable housing policy,
There is great uncertainty as to whether the operation of the project will meet expectations after completion. In view of the total investment amount of this project
The company has re-evaluated the feasibility of the project and after careful consideration, the company plans to terminate the project.
After the project is terminated, there may be losses in early project expenses (3.7022 million yuan paid, 3.4 million yuan to be paid
yuan, a total of 7.1022 million yuan), it is necessary to negotiate with the cooperative unit to terminate the contract early, which may cause contract disputes
and other risks. Currently, the company has sought alternatives to address its employees’ housing needs, and was originally planned for the project.
The construction funds will be used for the development of the company's main business and enhance the company's core competitiveness. The project can be terminated
Reduce the company's financial risks to a certain extent, and it is not expected to have any significant adverse effects on the company's financial and operating conditions.
There is no beneficial impact and no harm to the interests of the company or its shareholders, especially small and medium-sized shareholders.
Voting results: 11 votes in favor, 0 votes against, and 0 abstentions. This motion was approved.
Announcement is hereby made.
Board of Directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
June 22, 2026